Zenas BioPharma Quarterly Balance Sheet
NASDAQ: ZBIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Zenas BioPharma financial position
As of Jun 30, 2026, Zenas BioPharma reported total assets of $701.7 million, up 139.4% from a year earlier against total liabilities of $454.6 million. Shareholders' equity stood at $247.1 million, or 35.2% of assets. The company held $196.6 million in cash and equivalents against $223.0 million of debt, a net debt position of $26.4 million.
The current ratio (current assets divided by current liabilities) was 9.93, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.90.
Summary generated from market data by MetaCap's automated system. Methodology
Zenas BioPharma balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 196.58M | 500.22M | 110.64M | 115.56M | 44.01M | 196.55M | 319.74M | 360.04M | 183.93M | 37.15M | 56.86M | 72.31M |
| Short-Term Investments | 446.55M | 216.98M | 232.55M | 175.32M | 229.27M | 115.83M | 31.02M | 26.76M | — | — | — | — |
| Total Current Assets | 653.79M | 730.16M | 351.17M | 296.64M | 278.60M | 317.81M | 355.92M | 393.78M | — | — | 59.80M | — |
| Property, Plant & Equipment | 23.00K | 28.00K | 34.00K | 50.00K | 61.00K | 72.00K | 185.00K | 146.00K | — | — | 193.00K | — |
| Long-Term Investments | 30.76M | 1.34M | 17.27M | 10.72M | 1.61M | 1.83M | — | 0 | — | — | — | — |
| Total Assets | 701.69M | 747.68M | 383.64M | 322.02M | 293.08M | 333.77M | 369.97M | 403.43M | — | — | 68.18M | — |
| Accounts Payable | 7.59M | 8.94M | 7.11M | 6.44M | 7.93M | 20.02M | 17.14M | 15.08M | — | — | 5.40M | — |
| Total Current Liabilities | 65.82M | 61.16M | 62.65M | 52.42M | 53.24M | 49.13M | 57.29M | 44.00M | — | — | 23.26M | — |
| Long-Term Debt | 222.96M | 193.63M | 78.64M | 72.99M | — | — | — | — | — | — | — | — |
| Total Liabilities | 454.59M | 411.85M | 141.50M | 125.59M | 53.46M | 49.45M | 57.51M | 44.00M | — | — | 43.81M | — |
| Shareholders' Equity | 247.10M | 335.83M | 242.14M | 196.43M | 239.63M | 284.32M | 312.46M | 359.44M | -288.78M | -252.50M | -225.72M | -202.23M |
| Retained Earnings | -957.57M | -846.12M | -765.13M | -524.69M | -473.19M | -420.96M | -387.39M | -334.79M | — | — | -230.40M | — |
| Total Debt | 222.96M | 193.63M | 78.64M | 72.99M | — | — | — | — | — | — | — | — |
| Net Cash (Debt) | 420.17M | 523.57M | 264.56M | 217.90M | 273.28M | 312.38M | 350.77M | 386.80M | 183.93M | 37.15M | 56.86M | 72.31M |
| Shares Outstanding | 63.33M | 62.38M | 54.49M | 42.21M | 42.09M | 41.82M | 41.79M | 41.78M | — | — | 1.58M | — |
This table shows 12 quarterly periods of Zenas BioPharma's balance sheet, from Q2 2026 back to Q3 2023, across 15 line items including cash & equivalents, short-term investments, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow ZBIO's reporting calendar. What is a balance sheet?